Nxera Achieves Key Milestone In Eli Lilly Collaboration For Diabetes And Metabolic Disease Drug Development

Nxera Pharma Co., Ltd. has announced the achievement of a second development milestone under its multi-target collaboration with Eli Lilly and Company focused on diabetes and metabolic diseases. While the exact payment amount remains undisclosed, the milestone marks significant progress in Nxera’s research and development efforts.

The partnership, established in 2022, combines Nxera’s expertise in GPCR-focused structure-based drug design with Lilly’s capabilities in development and commercialization. The latest milestone highlights the successful application of Nxera’s proprietary NxWave™ platform, which enables the identification of small-molecule binders to GPCR targets and provides detailed insights into receptor-binding structures.

With this advancement, Lilly will take the lead in further development and commercialization of the program. The collaboration underscores the potential of structure-based approaches in accelerating drug discovery for complex metabolic conditions.

Under the agreement terms, Nxera is eligible to receive up to $694 million in development and commercial milestone payments, along with tiered royalties on future global sales, reflecting the long-term value of the partnership.